Lotivibart vs UVAX-1107

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV envelope · full HIV pipeline

Lotivibart

Developed by ViiV Healthcare

Phase 2 in HIVmonoclonal antibody
Weak signal

NCT04871113 · Phase 2 · completed

Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.

Next expected readout: January 2027 · NCT07053384 (registry estimate)

Reported efficacy

Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Adverse Events (AEs) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase): Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) (not_applicable)

Result source: NCT04871113

UVAX-1107

Developed by Uvax Bio

Phase 1 in HIVProtein nanoparticle vaccine
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLotivibartUVAX-1107
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Lotivibart
—Not reported
UVAX-1107
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Lotivibart
—Not reported
UVAX-1107
—Not reported

CD4 count, change (week 48)

Lotivibart
—Not reported
UVAX-1107
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

UVAX-1107: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lotivibart: 3 of 4 rows · UVAX-1107: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLotivibart
Dropout rate
—700 mg IVa
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
—700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
12.5%3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
0%60 mg/kg
NCT05291520 · Phase 1 · monotherapy
0%20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Discontinued due to AEs
—700 mg IVa
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
—700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
—40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
—3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
—60 mg/kg
NCT05291520 · Phase 1 · monotherapy
—20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Serious AEs
0%700 mg IVa
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
0%700 mg SC
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
18.8%700 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
25%700 mg SC
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
0%280 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%70 mg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
12.5%70 mg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%40 mg/kg IV
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
12.5%40 mg/kg IV
NCT04871113 · Phase 2 · combination · HIV · phase 2
0%3000 mg + rHuPH20
NCT05291520 · Phase 1 · combination
0%60 mg/kg
NCT05291520 · Phase 1 · monotherapy
0%20 mg/kg + rHuPH20
NCT05291520 · Phase 1 · combination
Most frequent reported AEs
700 mg IVa
influenza 12.5%
rhinitis 12.5%
aspartate aminotransferase increased 6.3%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 12 more results
700 mg SC
headache 18.8%
blood creatine phosphokinase increased 12.5%
neutropenia 12.5%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
700 mg IV
upper respiratory tract infection 18.8%
anaemia 12.5%
anogenital warts 6.3%
NCT04871113 · Phase 2 · combination · HIV · phase 2
700 mg SC
neutropenia 12.5%
pharyngitis 12.5%
tonsillitis 12.5%
NCT04871113 · Phase 2 · combination · HIV · phase 2
280 mg IV
abdominal pain 16.7%
asthenia 16.7%
bronchitis 16.7%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
280 mg IV
depression 16.7%
hypertension 16.7%
influenza like illness 16.7%
NCT04871113 · Phase 2 · combination · HIV · phase 2
70 mg IV
covid-19 12.5%
alanine aminotransferase increased 6.3%
anal abscess 6.3%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
70 mg IV
upper respiratory tract infection 12.5%
vomiting 12.5%
abdominal pain 6.3%
NCT04871113 · Phase 2 · combination · HIV · phase 2
40 mg/kg IV
abdominal pain 12.5%
blood creatine phosphokinase increased 12.5%
covid-19 12.5%
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
40 mg/kg IV
covid-19 25%
proctitis gonococcal 25%
syphilis 25%
NCT04871113 · Phase 2 · combination · HIV · phase 2
3000 mg + rHuPH20
injection site erythema 100%
injection site bruising 25%
injection site pain 25%
NCT05291520 · Phase 1 · combination
60 mg/kg
medical device site dermatitis 12.5%
muscle tightness 12.5%
covid-19 0%
NCT05291520 · Phase 1 · monotherapy
20 mg/kg + rHuPH20
injection site erythema 87.5%
upper respiratory tract infection 25%
headache 12.5%
NCT05291520 · Phase 1 · combination

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lotivibart

HIV-1 RNA -25966 copies/mL @ 12wk700 mg IV
absolute change · copies/mL
No placebo or comparator arm
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 4 more results
-12584 copies/mL @ 12wk700 mg SC
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-26826.5 copies/mL @ 12wk280 mg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-14720.5 copies/mL @ 12wk70 mg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-12014.5 copies/mL @ 12wk40 mg/kg IV
Maximum decline from baseline (up to Day 84/end of Monotherapy Phase)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
CD4+ -3.3 cells/uL @ 12wk700 mg IV
absolute change · cells/uL
No placebo or comparator arm
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
show 4 more results
-19.6 cells/uL @ 12wk700 mg SC
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
30.2 cells/uL @ 12wk280 mg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
-54.3 cells/uL @ 12wk70 mg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
31.8 cells/uL @ 12wk40 mg/kg IV
CD4+, Day 84/end of Monotherapy Phase (compared with baseline)
NCT04871113 · Phase 2 · monotherapy · HIV · phase 2
CD4+ 134.9 cells/uL @ 48wk700 mg IV
absolute change · cells/uL
No placebo or comparator arm
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
show 4 more results
247.3 cells/uL @ 48wk700 mg SC
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
180.4 cells/uL @ 48wk280 mg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
233.8 cells/uL @ 48wk70 mg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2
140 cells/uL @ 48wk40 mg/kg IV
CD4+, Week 48 of SOC Phase (compared with baseline)
NCT04871113 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lotivibart's landscape · UVAX-1107's landscape